Searched for
ASTRAZENECA PHARMA STOCK OUTLOOK
Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- US Stock Market: Fed's Goolsbee says inflation outlook hinges on tariffs, services pricesChicago Fed's Austan Goolsbee highlighted the central bank's primary challenge: discerning if inflation's current surge will persist or fad...
- Sensex trades on choppy note, Nifty below 24,100 as IT stocks drag benchmarks lowerIndian stock markets saw a subdued trading session on Tuesday, with the Sensex and Nifty experiencing minor dips, primarily due to losses i...
- Sensex rises 291 points, Nifty closes above 24,100; Tech Mahindra, Sun Pharma among top gainersIndian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...
- Top Nifty50 stocks analysts suggest buying in this volatile weekStock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, ...
- Reliance, financials and defence top investment picks as market leadership broadens: Rahul ShahReliance Industries is poised for a turnaround, with strong earnings, a Jio Platforms IPO, and AI/energy investments promising significant ...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- 9 Sensex stocks with up to 40% upside potential. Are these in your portfolio?Analyst target prices suggest several Sensex heavyweights could offer strong upside over the next 12 months. Based on Trendlyne consensus e...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- Accenture cuts revenue outlook, stock crashes 17%Accenture has lowered its annual revenue growth forecast. Companies are still cautious about spending on technology. This is happening even...
- Ahead of Market: 10 things that will decide stock market action on FridayIndian equities ended higher for a fifth straight session, recovering early losses despite hawkish Federal Reserve comments. Banking stocks...
- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- IT rebound may lack legs, outlook remains cautious: Sunil SinghaniaSpeaking at the ET NOW Markets Summit 2026, Singhania said that although valuations in the sector have become more reasonable after the sha...
- Ahead of Market: 10 things that will decide stock market action on MondayMarkets rallied sharply as easing US–Iran tensions and softer crude prices boosted sentiment. Sensex and Nifty surged 2%, adding Rs 10 lakh...
- AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Load More
